Andrea Ellis, Director at BridgeBio Pharma, Inc. (BBIO), sold 17,167 shares at $84.00 ($1.4M) on 2026-07-09, disclosed to the SEC on 2026-07-13.
Scheduled sale ($1.4M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| BBIO | SELL | 2025-04-16 | $350K | — | Filing → |
| BBIO | SELL | 2025-04-03 | $2.0M | — | Filing → |
| BBIO | BUY | 2022-03-17 | $101K | — | Filing → |